$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000162828022029546 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.219M	$2.253M
YoY Change	-13.01%	-10.02%
% of Gross Profit
Research & Development	$4.687M	$5.310M
YoY Change	7.23%	-10.23%
% of Gross Profit
Depreciation & Amortization	$33.00K	$32.00K
YoY Change	-19.51%	-15.79%
% of Gross Profit
Operating Expenses	$6.932M	$7.563M
YoY Change	-0.4%	-10.17%
Operating Profit		-$7.563M
YoY Change		-10.17%
Interest Expense	$137.0K	$175.0K
YoY Change	-179.19%	-16.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.795M	-$7.551M
YoY Change	-4.74%	-12.48%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.795M	-$7.551M
YoY Change	-4.74%	-12.48%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.50
Diluted Earnings Per Share	-$0.40	-$0.50
COMMON SHARES
Basic Shares Outstanding	16.84M shares	14.63M shares
Diluted Shares Outstanding		14.97M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.16M	$45.32M
YoY Change	-35.15%	26.43%
Cash & Equivalents	$24.23M	$20.01M
Short-Term Investments	$14.93M	$25.31M
Other Short-Term Assets	$4.919M	$977.0K
YoY Change	176.35%	-8.35%
Inventory
Prepaid Expenses	$3.010M	$3.010M
Receivables
Other Receivables
Total Short-Term Assets	$44.08M	$49.37M
YoY Change	-32.43%	23.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$536.0K	$513.0K
YoY Change	90.75%	85.2%
Goodwill
YoY Change
Intangibles	$62.00K	$67.00K
YoY Change	-25.3%	-24.72%
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change	-100.0%
Total Long-Term Assets	$2.637M	$2.754M
YoY Change	-18.08%	-9.88%
TOTAL ASSETS
Total Short-Term Assets	$44.08M	$49.37M
Total Long-Term Assets	$2.637M	$2.754M
Total Assets	$46.72M	$52.13M
YoY Change	-31.76%	21.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$175.0K	$796.0K
YoY Change	-38.6%	35.84%
Accrued Expenses	$961.0K	$615.0K
YoY Change	17.05%	-20.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.511M	$4.478M
YoY Change		-4.07%
Total Short-Term Liabilities	$11.66M	$10.52M
YoY Change	123.02%	-8.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.66M	$10.52M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$13.43M	$12.46M
YoY Change	-0.53%	-11.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$483.2M	-$476.4M
YoY Change	6.23%	6.4%
Common Stock	$516.5M	$516.1M
YoY Change	1.31%	8.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$33.29M	$39.67M
YoY Change
Total Liabilities & Shareholders Equity	$46.72M	$52.13M
YoY Change	-31.76%	21.11%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$6.795M	-$7.551M
YoY Change	-4.74%	-12.48%
Depreciation, Depletion And Amortization	$33.00K	$32.00K
YoY Change	-19.51%	-15.79%
Cash From Operating Activities	-$6.253M	-$6.733M
YoY Change	-20.15%	21.05%
INVESTING ACTIVITIES
Capital Expenditures	$63.00K	-$3.000K
YoY Change	-253.66%	-88.46%
Acquisitions
YoY Change
Other Investing Activities	$10.53M	-$12.86M
YoY Change
Cash From Investing Activities	$10.47M	-$12.86M
YoY Change	-25629.27%	49365.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	4.489M
YoY Change	-100.0%	-112325.0%
NET CHANGE
Cash From Operating Activities	-6.253M	-6.733M
Cash From Investing Activities	10.47M	-12.86M
Cash From Financing Activities	0.000	4.489M
Net Change In Cash	4.214M	-15.10M
YoY Change	-82.82%	170.12%
FREE CASH FLOW
Cash From Operating Activities	-$6.253M	-$6.733M
Capital Expenditures	$63.00K	-$3.000K
Free Cash Flow	-$6.316M	-$6.730M
YoY Change	-18.92%	21.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35670
	dei	Entity Registrant Name EntityRegistrantName	Regulus Therapeutics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-4738379
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4224 Campus Point Court, Suite 210
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	202-6300
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	RGLS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16840261	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20014000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60383000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	25310000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3010000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3010000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	977000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1780000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	49373000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	65235000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	513000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	281000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	67000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	83000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2174000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2564000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	291000	usd
CY2022Q3	us-gaap	Assets Assets	52127000	usd
CY2021Q4	us-gaap	Assets Assets	68454000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	796000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	285000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	615000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	821000	usd
CY2022Q3	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1081000	usd
CY2021Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	810000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1698000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2016000	usd
CY2022Q3	us-gaap	Debt Current DebtCurrent	4478000	usd
CY2021Q4	us-gaap	Debt Current DebtCurrent	0	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1853000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1295000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10521000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5227000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4673000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1936000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2417000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1179000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	12457000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Liabilities Liabilities	13496000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16840261	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16840261	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14597118	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14597118	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	17000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	516060000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	509791000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-476381000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-454853000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	39670000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	54958000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52127000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68454000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5310000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5915000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13697000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13385000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2253000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2504000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7610000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7471000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	7563000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	8419000	usd
	us-gaap	Operating Expenses OperatingExpenses	21307000	usd
	us-gaap	Operating Expenses OperatingExpenses	20856000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7563000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8419000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21307000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20856000	usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	187000	usd
CY2021Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	1000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	272000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	823000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	175000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	210000	usd
	us-gaap	Interest Expense InterestExpense	492000	usd
	us-gaap	Interest Expense InterestExpense	641000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21527000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20674000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7551000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8628000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7551000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8628000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21528000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20675000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	5000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-31000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7546000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8628000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21559000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20675000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.63
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.63
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14969574	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14969574	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8703637	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8703637	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14727591	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14727591	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7855479	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7855479	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	54958000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1000000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6719000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	49241000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	420000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-7258000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-36000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	42367000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4488000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	360000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7551000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	5000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	39670000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	usd
CY2021Q1	rgls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	666000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5713000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	691000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6013000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	27111000	usd
CY2021Q2	rgls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	166000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14831000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	754000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6034000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	36828000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	807000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8628000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	29012000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21528000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20675000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	89000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	418000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1780000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2252000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-52000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	rgls	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness	0	usd
	rgls	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness	662000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	101000	usd
	rgls	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness	662000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	39000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	0	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-503000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	0	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-304000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-802000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-784000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	511000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	51000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-217000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	193000	usd
	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	271000	usd
	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	1250000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-319000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-316000	usd
	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	-46000	usd
	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	291000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-665000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-729000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19273000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16297000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	30289000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5000000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	298000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	210000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25587000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-210000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4491000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21384000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	usd
	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	0	usd
	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	81000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4491000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21330000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40369000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4823000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60445000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31087000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20076000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35910000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20014000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35848000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20076000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35910000	usd
	rgls	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	348000	usd
	us-gaap	Interest Paid Net InterestPaidNet	329000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
	rgls	Financingfrom Sale Proceeds Debt Agreement Revenues FinancingfromSaleProceedsDebtAgreementRevenues	542500000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	45300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Additionally, the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty.</span></div>
	rgls	Number Of Amendments NumberOfAmendments	10	amendment
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13229539	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13229539	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9050339	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9050339	shares
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	25341000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	25310000	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	42618000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	57905000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16840261	shares
CY2022Q3	rgls	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1386000	shares
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13884000	shares
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	360000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	807000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1780000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2252000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	800000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	824000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	191000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	776000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	277000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2868000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	298000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2570000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	634000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1936000	usd

Files In Submission

Name	View Source	Status
0001628280-22-029546-index-headers.html	Edgar Link	pending
0001628280-22-029546-index.html	Edgar Link	pending
0001628280-22-029546.txt	Edgar Link	pending
0001628280-22-029546-xbrl.zip	Edgar Link	pending
ex-311x20220930.htm	Edgar Link	pending
ex-312x20220930.htm	Edgar Link	pending
ex-321x20220930.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20220930.htm	Edgar Link	pending
rgls-20220930.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rgls-20220930_cal.xml	Edgar Link	unprocessable
rgls-20220930_def.xml	Edgar Link	unprocessable
rgls-20220930_lab.xml	Edgar Link	unprocessable
rgls-20220930_pre.xml	Edgar Link	unprocessable
rgls-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2022 Q4 Form 10-Q Financial Statement

#000162828022029546 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2022 Q4 Form 10-Q Financial Statement

#000162828022029546 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls